Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model,
From offices in North Carolina and Hangzhou, the start-up will in-license compounds to sell in China while developing its own candidates.
From offices in North Carolina and Hangzhou, the start-up will in-license compounds to sell in China while developing its own candidates.